MedTech Surgery Franchise — Restructuring (Note 12)
Business Segments · Restructuring (Note 12)Johnson & Johnson MedTech Surgery Franchise — Restructuring (Note 12) increased by 341.4% to $128.00M in Q3 2025 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase indicates significant ongoing organizational change or cost-cutting efforts, while a decrease suggests that restructuring activities are winding down or that the business has reached a more stable operational state.
Detailed definition
This metric represents the specific costs and financial impacts associated with organizational restructuring initiatives...
Peer comparison
Peers in the medical device sector frequently report similar restructuring charges during periods of portfolio optimization or post-acquisition integration, often categorized as special items or non-recurring operating expenses.
jnj_segment_medtech_surgery_franchise_restructuring_note_12Historical Data
| Q2 '24 | Q3 '24 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|
| Value | $0.00 | $0.00 | $29.00M | $128.00M |
| QoQ Change | — | — | — | +341.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's medtech surgery franchise — restructuring (note 12)?
- Johnson & Johnson (JNJ) reported medtech surgery franchise — restructuring (note 12) of $128.00M in Q3 2025.
- What does medtech surgery franchise — restructuring (note 12) mean?
- The costs incurred from reorganizing and streamlining operations within the MedTech Surgery business division.